Abstract:Abstract Introduction Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pathognomonic motor abnormalities that lead to significant disability and morbidity in advanced stages. PD is also associated with sleep abnormalities such as increased fragmentation, insomnia, and excessive daytime sleepiness. Little is known of the underlying mechanisms, in part due to the limited ability of existing mouse models to adequately replicate human PD patient sleep phenotypes. Here we characterize sleep-wake behavior in an innovative genetic mouse model of PD (MCI-Park) targeting a mitochondrial complex I gene (Ndufs2), which experiences progressive dopaminergic neuron loss and displays motor phenotypes resembling those seen in human PD. Methods Undisturbed sleep-wake behavior during 12 hr light: 12 hr dark cycles was evaluated in MCI-Park mice during prodromal stages (6-8 weeks of age) and later parkinsonian stages (14-18 weeks of age) as well as in age-matched wildtype littermate controls. Electroencephalographic (EEG) and electromyographic (EMG) recording electrodes were surgically implanted using sterile technique in male and female MCI-Park and wildtype mice. After one week of recovery and acclimation to recording chambers, EEG and EMG were recorded continuously and sleep phenotypes were analyzed. Results In prodromal stages, MCI-Park mice exhibited similar overall sleep state amounts compared to wildtype mice, however there were significantly more state shifts as well as longer bouts of wakefulness and shorter bouts of non-REM (NREM) sleep. As mice progressed to parkinsonian stages, these fragmentation measures worsened. In addition, parkinsonian MCI-Park mice experienced a significant increase in wakefulness, a significant reduction in NREM sleep amount, and alterations in REM sleep, with pronounced reductions in REM sleep amount and number of REM bouts. Power spectral analysis revealed consistent decreases in theta2 (also known as alpha) power across all sleep-wake states in MCI-Park mice. Conclusion These results indicate that mice harboring a genetic defect causing selective disruption of dopaminergic neurons exhibit progressive sleep abnormalities that resemble sleep disturbances in PD patients. This model thus offers an opportunity to evaluate mechanisms underlying and therapeutic strategies targeting altered sleep in PD patients. Support (if any) This work was supported by the Department of Defense award number W81XWH-21-0582 (F.W.T. and D.J.S.).

Sleep deprivation induces late deleterious effects in a pharmacological model of Parkinsonism

Female Rats Are Resistant to Cognitive, Motor and Dopaminergic Deficits in the Reserpine-Induced Progressive Model of Parkinson’s Disease

Altered Motor Performance, Sleep EEG, and Parkinson's Disease Pathology Induced by Chronic Sleep Deprivation in Lrrk2G2019S Mice

Preclinical Reserpine Models Recapitulating Motor and Non-Motor Features of Parkinson's Disease: Roles of Epigenetic Upregulation of Alpha-Synuclein and Autophagy Impairment.

Preclinical reserpine models recapitulating motor and non-motor features of Parkinson’s disease: Roles of epigenetic upregulation of alpha-synuclein and autophagy impairment

Behavioral effects of 6-hydroxydopamine-induced damage to nigro-striatal pathway and Locus coeruleus as a rodent model of Parkinson's disease.

0258 Altered sleep regulation in a mouse model of Parkinson’s disease

Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson’s Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression

Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson´s disease

Wider and Faster Degeneration of White Matter in Parkinson’s Disease with Possible REM Sleep Behaviour Disorder

Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson's disease.

Serotonergic and dopaminergic neurons in the dorsal raphe are differentially altered in a mouse model for parkinsonism

Acute 2-phenyl-3-(phenylselanyl)benzofuran treatment reverses the neurobehavioral alterations induced by sleep deprivation in mice

Circadian dysfunction in a mouse model of Parkinson's disease

Reserpine-induced rat model for depression: Behavioral, physiological and PET-based dopamine receptor availability validation

Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans

Acute total sleep deprivation potentiates cocaine-induced hyperlocomotion in mice

Noradrenergic Dysfunction Accelerates LPS-elicited Inflammation-Related Ascending Sequential Neurodegeneration and Deficits in Non-Motor/motor Functions.

Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease

Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease

Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease